Corient Private Wealth LP Acquires Shares of 65,759 West Pharmaceutical Services, Inc. $WST

Corient Private Wealth LP bought a new position in West Pharmaceutical Services, Inc. (NYSE:WST) in the second quarter, Holdings Channel reports. The firm bought 65,759 shares of the medical instruments supplier’s stock, valued at approximately $23,607,000.

A number of other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in West Pharmaceutical Services in the 2nd quarter worth about $2,387,990,000. Bank of New York Mellon Corp bought a new position in West Pharmaceutical Services during the second quarter worth about $733,733,000. Generation Investment Management LLP bought a new position in West Pharmaceutical Services during the second quarter worth about $728,168,000. Norges Bank purchased a new position in shares of West Pharmaceutical Services in the fourth quarter worth about $272,041,000. Finally, Findlay Park Partners LLP bought a new stake in shares of West Pharmaceutical Services in the second quarter valued at approximately $214,196,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Stock Performance

NYSE:WST opened at $338.21 on Friday. The stock has a market cap of $23.80 billion, a P/E ratio of 43.30, a PEG ratio of 2.42 and a beta of 1.15. The company has a quick ratio of 2.12, a current ratio of 2.82 and a debt-to-equity ratio of 0.07. The business’s 50-day moving average price is $350.55 and its two-hundred day moving average price is $303.61. West Pharmaceutical Services, Inc. has a twelve month low of $223.83 and a twelve month high of $386.00.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, topping the consensus estimate of $2.08 by $0.29. The company had revenue of $872.30 million during the quarter, compared to analyst estimates of $839.98 million. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.West Pharmaceutical Services’s revenue was up 13.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.84 earnings per share. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. As a group, equities analysts predict that West Pharmaceutical Services, Inc. will post 8.93 EPS for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were paid a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend was Wednesday, July 29th. West Pharmaceutical Services’s payout ratio is currently 11.27%.

Analysts Set New Price Targets

A number of research firms recently weighed in on WST. BNP Paribas Exane started coverage on shares of West Pharmaceutical Services in a research note on Monday, July 13th. They issued an “outperform” rating and a $447.00 price objective for the company. Weiss Ratings upgraded West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, August 7th. TD Cowen reissued a “buy” rating on shares of West Pharmaceutical Services in a report on Wednesday, July 15th. Morgan Stanley lifted their target price on West Pharmaceutical Services from $325.00 to $365.00 and gave the company an “equal weight” rating in a report on Thursday, July 9th. Finally, Zacks Research cut West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $368.08.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.